ProQR Therapeutics N.V. (PRQR) director files Form 3 for options
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
ProQR Therapeutics N.V. director Bart Filius filed an initial ownership report detailing his stock option holdings. The Form 3 lists multiple options to purchase ordinary shares at fixed exercise prices, with expiration dates ranging from 2029 through 2035.
One option grant is noted as fully vested, while others vest 25% on specific January 1 dates from 2024 through 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to his continued service. The filing reports holdings only and does not show any recent share purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Filius Bart
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 12,755 shares (Direct)
Footnotes (1)
- Fully vested. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
FAQ
What does the ProQR (PRQR) Form 3 filing by Bart Filius show?
The Form 3 shows that director Bart Filius holds several stock options to buy ProQR ordinary shares at fixed exercise prices, expiring between 2029 and 2035. It is an initial ownership report and does not disclose any recent stock purchases or sales.
What stock option vesting terms are disclosed for ProQR director Bart Filius?
The filing notes one grant is fully vested. Other grants vest 25% on January 1 of 2024, 2025, 2026 or 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, contingent on his continued service with ProQR.
What types of securities are reported in the ProQR (PRQR) Form 3?
The Form 3 reports share options (rights to buy) over ProQR ordinary shares. Each option series has a specified exercise price and expiration date, and all reported positions are held directly by director Bart Filius, according to the ownership details provided.
Why is ProQR director Bart Filius filing this Form 3?
Form 3 is an initial statement of beneficial ownership required for insiders. This filing records director Bart Filius’s existing stock option holdings in ProQR, giving investors transparency into his equity-based compensation and potential future right to acquire ordinary shares.